title: In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
abstract: We examined 300 strains of Neisseria gonorrhoeae and 100 strains of Haemophilus ducreyi to determine their in vitro susceptibility to two new cephalosporins, cefetamet (Ro 15-8074) and ceftetrame (Ro 19-5247; T-2588), and a new fluroquinolone, fleroxacin (Ro 23-6240; AM-833). Their activity was compared with that of ceftriaxone, penicillin, spectinomycin, tetracycline, and erythromycin. Cefetamet, ceftetrame, and fleroxacin had excellent in vitro activity against both groups of microorganisms. beta-Lactamase production did not significantly affect the MICs of these agents. The Mtr phenotype of N. gonorrhoeae raised the MICs two- to fourfold, but the MICs remained within the range of achievable levels in serum. These newer compounds have a distinct advantage over existing therapeutic agents in that they can be administered orally. Clinical trials are warranted to assess their usefulness in the therapy of gonorrhea and chancroid.
mesh_terms: D015281:Cefmenoxime / Q000031:analogs & derivatives*; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002443:Ceftriaxone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D016576:Fleroxacin; D006191:Haemophilus ducreyi / Q000187:drug effects*; D006801:Humans; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D010406:Penicillins / Q000494:pharmacology; D000198:Spectinomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology
chemical_list: D002511:Cephalosporins; D010406:Penicillins; C047444:cefetamet; D002939:Ciprofloxacin; D004917:Erythromycin; C049493:cefteram; D002443:Ceftriaxone; D000198:Spectinomycin; D015296:Ceftizoxime; D013752:Tetracycline; D015281:Cefmenoxime; D016576:Fleroxacin